<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579393</url>
  </required_header>
  <id_info>
    <org_study_id>10000110</org_study_id>
    <secondary_id>000110-H</secondary_id>
    <nct_id>NCT04579393</nct_id>
  </id_info>
  <brief_title>Fostamatinib for Hospitalized Adults With COVID-19</brief_title>
  <official_title>A Phase II Study Evaluating Fostamatinib for Hospitalized Adults With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      COVID-19 is a new disease caused by SARS-CoV-2 that was identified in 2019. Some people who&#xD;
      get sick with COVID-19 become ill requiring hospitalization. There are some medicines that&#xD;
      may help with recovery. Researchers want to see if a drug called fostamatinib may help people&#xD;
      who are hospitalized with COVID-19.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To learn if fostamatinib is safe in patients who are hospitalized with COVID-19 and gain&#xD;
      earlier insight into whether it improves outcomes.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Adults age 18 and older who are hospitalized with COVID-19.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened with a physical exam, including vital signs and weight. They&#xD;
      will have a blood test and chest x-ray. They will have a COVID-19 test as a swab of either&#xD;
      the back of the throat or the back of the nose. They will take a pregnancy test if needed.&#xD;
&#xD;
      Participants will be randomly assigned, to take either fostamatinib pills or a placebo twice&#xD;
      daily for up to 14 days in addition to standard of care for COVID-19. If they can swallow,&#xD;
      they will take the pills by mouth with water. If they cannot swallow or are on mechanical&#xD;
      ventilation, the pills will be crushed, mixed with water, and given through a tube placed&#xD;
      through the nostril, or placed in the mouth, down the esophagus, and into the stomach. Blood&#xD;
      samples will be taken daily. Participants will return to the Clinical Center for safety&#xD;
      follow-up visits. At these visits, they will have a physical exam and blood tests. If they&#xD;
      cannot visit the Clinical Center, they will be contacted by phone or have a telehealth visit.&#xD;
&#xD;
      Participation will last for about two months&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronavirus Disease 2019 (COVID-19) is the disease caused by Severe Acute Respiratory&#xD;
      Syndrome Coronavirus-2 (SARS-CoV-2). SARS-CoV-2 primarily infects the upper and lower&#xD;
      respiratory tract and can lead to acute respiratory distress syndrome (ARDS) in a subset of&#xD;
      patients with a known high mortality rate. Additionally, some patients develop other organ&#xD;
      dysfunction including myocardial injury, acute kidney injury, shock along with endothelial&#xD;
      dysfunction and subsequently micro and macrovascular thrombosis.&#xD;
&#xD;
      Much of the underlying pathology of SARS-CoV-2 is thought to be secondary to a dysregulated&#xD;
      immune response and more recently a hypercoagulable state leading to immunothrombosis.&#xD;
      Currently, two therapies have shown efficacy in large multicenter trials for the treatment of&#xD;
      COVID-19, one of which is an antiviral (remdesivir) and the other is an immunosuppressant&#xD;
      corticosteroid meant to dampen the immune response (dexamethasone).&#xD;
&#xD;
      Spleen tyrosine kinase (SYK) is a cytoplasmic tyrosine kinase involved in the intracellular&#xD;
      signaling pathways of many different immune cells. In this pilot study we propose to use&#xD;
      fostamatinib (an SYK inhibitor) as a targeted therapy for the immunological complications of&#xD;
      hospitalized patients with COVID-19. The biological mechanisms by which SYK inhibition may&#xD;
      improve outcomes in patients with COVID-19 include the inhibition of pro-inflammatory&#xD;
      cytokines by monocytes and macrophages, decreased production of neutrophil extracellular&#xD;
      traps (NETs) by neutrophils, and inhibition of platelet aggregation; three pathways that are&#xD;
      mediated through Fc receptors (FcR) recognition of antigen-antibody complexes or activation&#xD;
      of c-type lectin receptors (CLEC).&#xD;
&#xD;
      This is a randomized, double-blind, placebo-controlled trial of fostamatinib for the&#xD;
      treatment of hospitalized patients with COVID-19.&#xD;
&#xD;
      We will randomly assign fostamatinib or matched placebo (1:1) to 60 eligible COVID-19&#xD;
      patients who are a 5 to 7 on the 8-point scale (requiring supplemental oxygen via nasal&#xD;
      canula or noninvasive ventilation, requiring mechanical ventilation or extracorporeal&#xD;
      membrane oxygenation).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With at Least 1 Serious Adverse Event</measure>
    <time_frame>Day 29</time_frame>
    <description>Number of participants with at least 1 serious adverse event by day 29 using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE is a list of common adverse event (AE) terms. Each AE term is defined and accompanied by a grading scale (1 to 5) that indicates the severity of the AE. Grading ranges from Grade 1 which is mild to Grade 5 which is death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Sustained Recoveries Defined by Ordinal Scale Score of 3 or Less</measure>
    <time_frame>day 29</time_frame>
    <description>Time to sustained recovery determined by ordinal scale score of 3 or less and defined as time to recovery [either discharge from the hospital or hospitalization for infection control reasons only], with the recovery status sustained through day 29.&#xD;
The ordinal scale is an assessment of the clinical status. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Progress to Mechanical Ventilation</measure>
    <time_frame>day 29</time_frame>
    <description>Number of participants who progress to mechanical ventilation by day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cumulative Clinical Endpoint of Death</measure>
    <time_frame>day 14, day 28, day 60</time_frame>
    <description>Number of Participants with Cumulative Clinical Endpoint of Death at Day 14, Day 28 and Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Grade 3 and 4 Adverse Events Through Day 60</measure>
    <time_frame>Day 60</time_frame>
    <description>Number of Grade 3 and 4 AE through day 60 using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE is a list of common adverse event (AE) terms. Each AE term is defined and accompanied by a grading scale (1 to 5) that indicates the severity of the AE. Grading ranges from Grade 1 which is mild to Grade 5 which is death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Score on Ordinal Scale</measure>
    <time_frame>Day 15, Day 29</time_frame>
    <description>Participant score on ordinal scale at day 15 and day 29. The ordinal scale is an assessment of the clinical status. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-Reactive Protein Levels From Baseline</measure>
    <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
    <description>Change in C-Reactive Protein (CRP) blood levels from baseline. The upper limit of normal is 5 mg/L (milligrams per liter).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibrinogen Levels From Baseline.</measure>
    <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
    <description>Change in Fibrinogen blood levels from baseline. The upper limit of normal is Fibrinogen 466 milligrams per decilitre (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D-Dimer Levels From Baseline</measure>
    <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
    <description>Change in D-Dimer blood levels from baseline. The upper limit of normal is 0.50 mcg/mL (microgram per milliliter).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ferritin Levels From Baseline</measure>
    <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
    <description>Change in Ferritin levels from baseline. The upper limit of normal for Ferritin is 400 mcg/L (micrograms per liter).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin 6 (IL6) Levels From Baseline</measure>
    <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
    <description>Change in Interleukin 6 (IL6) blood levels from baseline. The upper limit of normal for IL6 is 1.8 picograms per milliliter (pg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Days Participants Were Admitted to Intensive Care Unit</measure>
    <time_frame>Day 29</time_frame>
    <description>Median days participants were admitted to Intensive Care Unit (ICU) by day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change in SpO2/FiO2 Ratio</measure>
    <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
    <description>Relative change in PaO2/FiO2 or SpO2/FiO2 ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SOFA Score From Baseline</measure>
    <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
    <description>Change in SOFA score from baseline (day 1). The Sequential Organ Failure Assessment (SOFA) Score is a mortality prediction score that is based on the degree of dysfunction of six organ systems. The score is calculated on admission and every 24 hours until discharge using the worst parameters measured during the prior 24 hours. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). The &quot;worst&quot; measurement was defined as the measure that correlated to the highest number of points. The SOFA score ranges from 0 to 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Days on Participants Received Supplemental Oxygen</measure>
    <time_frame>day 29</time_frame>
    <description>Median days on participants received supplemental oxygen through day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants That Experienced Acute Renal Failure</measure>
    <time_frame>day 29</time_frame>
    <description>The number of participants that experienced acute renal failure by day 29.&#xD;
Acute renal failure defined as increase in serum creatinine by ≥0.3mg/dL within 48 hours or increase in serum creatinine by ≥1.5 times baseline which is known or presumed to have occurred within the prior seven days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Experienced a Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)</measure>
    <time_frame>day 29</time_frame>
    <description>Number of participants that experienced a deep vein thrombosis (DVT) or pulmonary embolism (PE) by day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Absolute Lymphocyte Count Levels From Baseline</measure>
    <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
    <description>Change in Absolute lymphocyte count blood levels from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Absolute Neutrophil Count Levels From Baseline</measure>
    <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
    <description>Change in Absolute neutrophil count blood levels from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Platelet Count Levels From Baseline</measure>
    <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
    <description>Change in Platelet count blood levels from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Coronavirus Disease 2019</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fostamatinib in combination with standard of care (SOC) for the treatment of COVID-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in combination with standard of care (SOC) for the treatment of COVID-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets to match fostamatinib 100 mg and 150 mg will be provided.</description>
    <arm_group_label>Intervention - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fostamatinib</intervention_name>
    <description>The study intervention is fostamatinib, an inhibitor of spleen tyrosine kinase that will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses. Subjects will receive standard of care and be randomized to receive fostamatinib or matching placebo.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Patient must be hospitalized, or had their inpatient stay extended, for COVID-19.&#xD;
&#xD;
               2. Age &gt;=18 years&#xD;
&#xD;
               3. Subject (or legally authorized representative) provides informed consent prior to&#xD;
                  initiation of any study procedures.&#xD;
&#xD;
               4. Subject (or legally authorized representative) understands and agrees to comply&#xD;
                  with planned study procedures.&#xD;
&#xD;
               5. Females of childbearing potential must agree to be abstinent or use a medical&#xD;
                  acceptable form of contraception from the time of enrollment through 30 days&#xD;
                  after last day of study drug&#xD;
&#xD;
               6. Laboratory confirmed SARS-CoV-2 RT-PCR test within 7 days of enrollment&#xD;
&#xD;
               7. Illness of any duration with SpO2 of less than 94% on room air requiring&#xD;
                  supplemental oxygen via nasal canula or non-invasive mechanical ventilation, or&#xD;
                  mechanical ventilation or ECMO (5 to 7 on the 8-point scale)&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. ALT or AST &gt; 5 times the upper limit of normal (ULN) or ALT or AST &gt;= 3 x ULN and&#xD;
             total bilirubin &gt; 2 x ULN.&#xD;
&#xD;
          2. Estimated glomerular filtration rate (eGFR) &lt;30ml/min&#xD;
&#xD;
          3. Pregnancy or breast feeding&#xD;
&#xD;
          4. Anticipated discharge in the next 72 hours&#xD;
&#xD;
          5. Allergy to study medication&#xD;
&#xD;
          6. Uncontrolled hypertension (systolic blood pressure &gt;160mmHg or diastolic blood&#xD;
             pressure &gt;100mmHg)&#xD;
&#xD;
          7. Shock or hypotension at the time of enrollment&#xD;
&#xD;
          8. Neutrophil count &lt;1000/microliter&#xD;
&#xD;
          9. Concern for bacterial or fungal sepsis&#xD;
&#xD;
         10. Received immunomodulatory treatment within 30 days prior to enrollment e.g., Bruton's&#xD;
             tyrosine kinase/phosphoinositide 3 kinase/Janus kinase inhibitor or cytokine-targeting&#xD;
             biologic therapy (anti-TNF, IL-6)&#xD;
&#xD;
         11. Received a live vaccine the last 4 weeks&#xD;
&#xD;
         12. Those who were cognitively impaired or mentally disabled prior to COVID diagnosis&#xD;
&#xD;
         13. Participation in another clinical trial for the treatment of COVID-19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey R Strich, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health Clinical Center (CC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INOVA Health Systems</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_000110-H.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <results_first_submitted>February 14, 2022</results_first_submitted>
  <results_first_submitted_qc>February 28, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">March 2, 2022</results_first_posted>
  <last_update_submitted>February 28, 2022</last_update_submitted>
  <last_update_submitted_qc>February 28, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Spleen Tyrosine Kinase</keyword>
  <keyword>ARDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT04579393/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 5, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT04579393/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from October 8, 2020, through March 2, 2021 across 2 centers: Inova Fairfax Hospital (Falls Church, VA) and the National Institutes of Health (NIH) Clinical Center (Bethesda, MD).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
          <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
        </group>
        <group group_id="P2">
          <title>Placebo With Standard of Care for Treatment of COVID-19</title>
          <description>Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
          <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
        </group>
        <group group_id="B2">
          <title>Placebo With Standard of Care for Treatment of COVID-19</title>
          <description>Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.3" spread="13.5"/>
                    <measurement group_id="B2" value="57.0" spread="14.1"/>
                    <measurement group_id="B3" value="55.6" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Score on Ordinal Scale</title>
          <description>The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Requiring supplemental oxygen</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Noninvasive ventilation or high-flow oxygen devices</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Invasive mechanical ventilation or extracorporeal membrane oxygen</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medication for COVID-19 other than the study drug</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Remdesivir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dexamethasone or other steroids (methylprednisolone and prednisone)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convalescent plasma or monoclonal antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least 1 Serious Adverse Event</title>
        <description>Number of participants with at least 1 serious adverse event by day 29 using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE is a list of common adverse event (AE) terms. Each AE term is defined and accompanied by a grading scale (1 to 5) that indicates the severity of the AE. Grading ranges from Grade 1 which is mild to Grade 5 which is death.</description>
        <time_frame>Day 29</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least 1 Serious Adverse Event</title>
          <description>Number of participants with at least 1 serious adverse event by day 29 using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE is a list of common adverse event (AE) terms. Each AE term is defined and accompanied by a grading scale (1 to 5) that indicates the severity of the AE. Grading ranges from Grade 1 which is mild to Grade 5 which is death.</description>
          <population>Intention-to-treat analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Sustained Recoveries Defined by Ordinal Scale Score of 3 or Less</title>
        <description>Time to sustained recovery determined by ordinal scale score of 3 or less and defined as time to recovery [either discharge from the hospital or hospitalization for infection control reasons only], with the recovery status sustained through day 29.&#xD;
The ordinal scale is an assessment of the clinical status. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.</description>
        <time_frame>day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Recoveries Defined by Ordinal Scale Score of 3 or Less</title>
          <description>Time to sustained recovery determined by ordinal scale score of 3 or less and defined as time to recovery [either discharge from the hospital or hospitalization for infection control reasons only], with the recovery status sustained through day 29.&#xD;
The ordinal scale is an assessment of the clinical status. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Progress to Mechanical Ventilation</title>
        <description>Number of participants who progress to mechanical ventilation by day 29</description>
        <time_frame>day 29</time_frame>
        <population>Participants who were not receiving mechanical ventilation at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Progress to Mechanical Ventilation</title>
          <description>Number of participants who progress to mechanical ventilation by day 29</description>
          <population>Participants who were not receiving mechanical ventilation at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cumulative Clinical Endpoint of Death</title>
        <description>Number of Participants with Cumulative Clinical Endpoint of Death at Day 14, Day 28 and Day 60</description>
        <time_frame>day 14, day 28, day 60</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cumulative Clinical Endpoint of Death</title>
          <description>Number of Participants with Cumulative Clinical Endpoint of Death at Day 14, Day 28 and Day 60</description>
          <population>Intention-to-treat analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Grade 3 and 4 Adverse Events Through Day 60</title>
        <description>Number of Grade 3 and 4 AE through day 60 using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE is a list of common adverse event (AE) terms. Each AE term is defined and accompanied by a grading scale (1 to 5) that indicates the severity of the AE. Grading ranges from Grade 1 which is mild to Grade 5 which is death.</description>
        <time_frame>Day 60</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Grade 3 and 4 Adverse Events Through Day 60</title>
          <description>Number of Grade 3 and 4 AE through day 60 using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE is a list of common adverse event (AE) terms. Each AE term is defined and accompanied by a grading scale (1 to 5) that indicates the severity of the AE. Grading ranges from Grade 1 which is mild to Grade 5 which is death.</description>
          <population>Intention-to-treat analysis</population>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Score on Ordinal Scale</title>
        <description>Participant score on ordinal scale at day 15 and day 29. The ordinal scale is an assessment of the clinical status. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.</description>
        <time_frame>Day 15, Day 29</time_frame>
        <population>intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Score on Ordinal Scale</title>
          <description>Participant score on ordinal scale at day 15 and day 29. The ordinal scale is an assessment of the clinical status. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.</description>
          <population>intent to treat analysis</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-Reactive Protein Levels From Baseline</title>
        <description>Change in C-Reactive Protein (CRP) blood levels from baseline. The upper limit of normal is 5 mg/L (milligrams per liter).</description>
        <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
        <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-Reactive Protein Levels From Baseline</title>
          <description>Change in C-Reactive Protein (CRP) blood levels from baseline. The upper limit of normal is 5 mg/L (milligrams per liter).</description>
          <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
          <units>mg/L (milligrams per liter)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37" lower_limit="-94" upper_limit="-6"/>
                    <measurement group_id="O2" value="-46" lower_limit="-105" upper_limit="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34" lower_limit="-84" upper_limit="5"/>
                    <measurement group_id="O2" value="-51" lower_limit="-128" upper_limit="-23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56" lower_limit="-108" upper_limit="-17"/>
                    <measurement group_id="O2" value="-66" lower_limit="-118" upper_limit="-39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52" lower_limit="-114" upper_limit="-29"/>
                    <measurement group_id="O2" value="-68" lower_limit="-139" upper_limit="-46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43" lower_limit="-109" upper_limit="-33"/>
                    <measurement group_id="O2" value="-71" lower_limit="-126" upper_limit="-47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65" lower_limit="-117" upper_limit="-33"/>
                    <measurement group_id="O2" value="-106" lower_limit="-155" upper_limit="-57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fibrinogen Levels From Baseline.</title>
        <description>Change in Fibrinogen blood levels from baseline. The upper limit of normal is Fibrinogen 466 milligrams per decilitre (mg/dL).</description>
        <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
        <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fibrinogen Levels From Baseline.</title>
          <description>Change in Fibrinogen blood levels from baseline. The upper limit of normal is Fibrinogen 466 milligrams per decilitre (mg/dL).</description>
          <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
          <units>mg/dL (milligrams per decilitre)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60" lower_limit="-177" upper_limit="-11"/>
                    <measurement group_id="O2" value="-65" lower_limit="-155" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-86" lower_limit="-187" upper_limit="2"/>
                    <measurement group_id="O2" value="-78" lower_limit="-245" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-130" lower_limit="-260" upper_limit="-34"/>
                    <measurement group_id="O2" value="-96" lower_limit="-236" upper_limit="-40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-141" lower_limit="-277" upper_limit="-77"/>
                    <measurement group_id="O2" value="-138" lower_limit="-250" upper_limit="-14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-132" lower_limit="-182" upper_limit="-24"/>
                    <measurement group_id="O2" value="-76" lower_limit="-214" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-113" lower_limit="-235" upper_limit="-63"/>
                    <measurement group_id="O2" value="-231" lower_limit="-351" upper_limit="-64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in D-Dimer Levels From Baseline</title>
        <description>Change in D-Dimer blood levels from baseline. The upper limit of normal is 0.50 mcg/mL (microgram per milliliter).</description>
        <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
        <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in D-Dimer Levels From Baseline</title>
          <description>Change in D-Dimer blood levels from baseline. The upper limit of normal is 0.50 mcg/mL (microgram per milliliter).</description>
          <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
          <units>mcg/mL (microgram per milliliter)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-0.19" upper_limit="0.25"/>
                    <measurement group_id="O2" value="-0.08" lower_limit="-0.4" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" lower_limit="-0.24" upper_limit="0.11"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.74" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-0.74" upper_limit="0.07"/>
                    <measurement group_id="O2" value="-0.24" lower_limit="-1.25" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" lower_limit="-0.56" upper_limit="0.12"/>
                    <measurement group_id="O2" value="-0.43" lower_limit="-0.99" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" lower_limit="-0.2" upper_limit="0.12"/>
                    <measurement group_id="O2" value="-0.32" lower_limit="-1.02" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-0.31" upper_limit="0"/>
                    <measurement group_id="O2" value="-0.16" lower_limit="-0.82" upper_limit="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ferritin Levels From Baseline</title>
        <description>Change in Ferritin levels from baseline. The upper limit of normal for Ferritin is 400 mcg/L (micrograms per liter).</description>
        <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
        <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ferritin Levels From Baseline</title>
          <description>Change in Ferritin levels from baseline. The upper limit of normal for Ferritin is 400 mcg/L (micrograms per liter).</description>
          <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
          <units>mcg/L (micrograms per liter)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-94" lower_limit="-306" upper_limit="20"/>
                    <measurement group_id="O2" value="-190" lower_limit="-622" upper_limit="-102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-213" lower_limit="-532" upper_limit="-25"/>
                    <measurement group_id="O2" value="-199" lower_limit="-684" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73" lower_limit="-428" upper_limit="438"/>
                    <measurement group_id="O2" value="-253" lower_limit="-586" upper_limit="-17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-169" lower_limit="-853" upper_limit="93"/>
                    <measurement group_id="O2" value="-491" lower_limit="-756" upper_limit="-239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-346" lower_limit="-904" upper_limit="4"/>
                    <measurement group_id="O2" value="-561" lower_limit="-882" upper_limit="-350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-578" lower_limit="-1038" upper_limit="-206"/>
                    <measurement group_id="O2" value="-738" lower_limit="-1562" upper_limit="-530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interleukin 6 (IL6) Levels From Baseline</title>
        <description>Change in Interleukin 6 (IL6) blood levels from baseline. The upper limit of normal for IL6 is 1.8 picograms per milliliter (pg/mL).</description>
        <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
        <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 6 (IL6) Levels From Baseline</title>
          <description>Change in Interleukin 6 (IL6) blood levels from baseline. The upper limit of normal for IL6 is 1.8 picograms per milliliter (pg/mL).</description>
          <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
          <units>pg/mL (picograms per milliliter)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-11.5" upper_limit="1.4"/>
                    <measurement group_id="O2" value="1.4" lower_limit="-2.6" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-16.1" upper_limit="4.4"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-1.8" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-5.5" upper_limit="3.8"/>
                    <measurement group_id="O2" value="-2.5" lower_limit="-6.6" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-9.9" upper_limit="1.4"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-8.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-5.5" upper_limit="1"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-4.3" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-6.5" upper_limit="-0.4"/>
                    <measurement group_id="O2" value="-1.4" lower_limit="-4" upper_limit="-0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Days Participants Were Admitted to Intensive Care Unit</title>
        <description>Median days participants were admitted to Intensive Care Unit (ICU) by day 29</description>
        <time_frame>Day 29</time_frame>
        <population>Participants admitted to Intensive Care Unit</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Days Participants Were Admitted to Intensive Care Unit</title>
          <description>Median days participants were admitted to Intensive Care Unit (ICU) by day 29</description>
          <population>Participants admitted to Intensive Care Unit</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="7" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change in SpO2/FiO2 Ratio</title>
        <description>Relative change in PaO2/FiO2 or SpO2/FiO2 ratio.</description>
        <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
        <population>Only SpO2/FiO2 ratio is available as PaO2 was not consistently measured. Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in SpO2/FiO2 Ratio</title>
          <description>Relative change in PaO2/FiO2 or SpO2/FiO2 ratio.</description>
          <population>Only SpO2/FiO2 ratio is available as PaO2 was not consistently measured. Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
          <units>SpO2/FiO2 ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.7" upper_limit="0.97"/>
                    <measurement group_id="O2" value="0.93" lower_limit="0.65" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="0.75" upper_limit="1.33"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.76" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.59" upper_limit="1.83"/>
                    <measurement group_id="O2" value="1.09" lower_limit="0.59" upper_limit="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="0.81" upper_limit="2.14"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.53" upper_limit="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.87" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.67" upper_limit="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.74" upper_limit="0.74"/>
                    <measurement group_id="O2" value="0.49" lower_limit="0.42" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SOFA Score From Baseline</title>
        <description>Change in SOFA score from baseline (day 1). The Sequential Organ Failure Assessment (SOFA) Score is a mortality prediction score that is based on the degree of dysfunction of six organ systems. The score is calculated on admission and every 24 hours until discharge using the worst parameters measured during the prior 24 hours. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). The &quot;worst&quot; measurement was defined as the measure that correlated to the highest number of points. The SOFA score ranges from 0 to 24.</description>
        <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
        <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SOFA Score From Baseline</title>
          <description>Change in SOFA score from baseline (day 1). The Sequential Organ Failure Assessment (SOFA) Score is a mortality prediction score that is based on the degree of dysfunction of six organ systems. The score is calculated on admission and every 24 hours until discharge using the worst parameters measured during the prior 24 hours. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). The &quot;worst&quot; measurement was defined as the measure that correlated to the highest number of points. The SOFA score ranges from 0 to 24.</description>
          <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
          <units>score on a SOFA scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-1" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="-1" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-2" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Days on Participants Received Supplemental Oxygen</title>
        <description>Median days on participants received supplemental oxygen through day 29</description>
        <time_frame>day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Days on Participants Received Supplemental Oxygen</title>
          <description>Median days on participants received supplemental oxygen through day 29</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="O2" value="20" lower_limit="14" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants That Experienced Acute Renal Failure</title>
        <description>The number of participants that experienced acute renal failure by day 29.&#xD;
Acute renal failure defined as increase in serum creatinine by ≥0.3mg/dL within 48 hours or increase in serum creatinine by ≥1.5 times baseline which is known or presumed to have occurred within the prior seven days.</description>
        <time_frame>day 29</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants That Experienced Acute Renal Failure</title>
          <description>The number of participants that experienced acute renal failure by day 29.&#xD;
Acute renal failure defined as increase in serum creatinine by ≥0.3mg/dL within 48 hours or increase in serum creatinine by ≥1.5 times baseline which is known or presumed to have occurred within the prior seven days.</description>
          <population>Intent to treat analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Experienced a Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)</title>
        <description>Number of participants that experienced a deep vein thrombosis (DVT) or pulmonary embolism (PE) by day 29</description>
        <time_frame>day 29</time_frame>
        <population>Intent to Treat Analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Experienced a Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)</title>
          <description>Number of participants that experienced a deep vein thrombosis (DVT) or pulmonary embolism (PE) by day 29</description>
          <population>Intent to Treat Analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Absolute Lymphocyte Count Levels From Baseline</title>
        <description>Change in Absolute lymphocyte count blood levels from baseline.</description>
        <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
        <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Absolute Lymphocyte Count Levels From Baseline</title>
          <description>Change in Absolute lymphocyte count blood levels from baseline.</description>
          <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
          <units>thousand cells per microliter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" lower_limit="0.02" upper_limit="0.64"/>
                    <measurement group_id="O2" value="0.13" lower_limit="-0.18" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.08" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.38" lower_limit="-0.14" upper_limit="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="0.06" upper_limit="1.22"/>
                    <measurement group_id="O2" value="0.34" lower_limit="-0.02" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.15" upper_limit="1.37"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.57" upper_limit="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.52" upper_limit="1.18"/>
                    <measurement group_id="O2" value="0.68" lower_limit="0.25" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" lower_limit="0.42" upper_limit="0.89"/>
                    <measurement group_id="O2" value="0.81" lower_limit="0.42" upper_limit="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Absolute Neutrophil Count Levels From Baseline</title>
        <description>Change in Absolute neutrophil count blood levels from baseline.</description>
        <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
        <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Absolute Neutrophil Count Levels From Baseline</title>
          <description>Change in Absolute neutrophil count blood levels from baseline.</description>
          <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
          <units>thousand cells per microliter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-1.22" upper_limit="1.06"/>
                    <measurement group_id="O2" value="-0.09" lower_limit="-2.06" upper_limit="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" lower_limit="-2.31" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0.94" lower_limit="-0.97" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="-3.4" upper_limit="3.78"/>
                    <measurement group_id="O2" value="2.74" lower_limit="-0.4" upper_limit="6.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" lower_limit="-2.34" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.85" lower_limit="-1.42" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" lower_limit="-3.41" upper_limit="-0.6"/>
                    <measurement group_id="O2" value="-1.6" lower_limit="-5.22" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.54" lower_limit="-4.62" upper_limit="-1.12"/>
                    <measurement group_id="O2" value="-2.89" lower_limit="-7.9" upper_limit="-0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Platelet Count Levels From Baseline</title>
        <description>Change in Platelet count blood levels from baseline.</description>
        <time_frame>Day 3, Day 5, Day 8, Day 11, Day 15, Day 29</time_frame>
        <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
            <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Standard of Care for Treatment of COVID-19</title>
            <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Platelet Count Levels From Baseline</title>
          <description>Change in Platelet count blood levels from baseline.</description>
          <population>Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment.</population>
          <units>thousand cells per microliter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="19" upper_limit="117"/>
                    <measurement group_id="O2" value="58" lower_limit="24" upper_limit="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103" lower_limit="55" upper_limit="150"/>
                    <measurement group_id="O2" value="63" lower_limit="1" upper_limit="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145" lower_limit="91" upper_limit="217"/>
                    <measurement group_id="O2" value="62" lower_limit="-34" upper_limit="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="20" upper_limit="156"/>
                    <measurement group_id="O2" value="25" lower_limit="-132" upper_limit="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="-30" upper_limit="92"/>
                    <measurement group_id="O2" value="-26" lower_limit="-198" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29" lower_limit="-87" upper_limit="42"/>
                    <measurement group_id="O2" value="-7" lower_limit="-102" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fostamatinib With Standard of Care for Treatment of COVID-19</title>
          <description>Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
        </group>
        <group group_id="E2">
          <title>Placebo With Standard of Care for Treatment of COVID-19</title>
          <description>Placebo: Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 5.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Self-Extubation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Post COVID Fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE 5.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Strich, MD</name_or_title>
      <organization>The National Institutes of Health / The National Heart, Lung, and Blood Institute</organization>
      <phone>301.496.9320</phone>
      <email>jeffrey.strich@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

